Researchers have identified potential new treatment targets for Alzheimer's disease and several FDA-approved drugs with therapeutic potential against them.

Tooth loss is a risk factor for dementia—and with each tooth lost, the risk of cognitive decline grows. But dentures may offer some protection.

Insight on how a unique protein plays a role in cellular stress responses may provide more clues on how to treat diseases like ALS and Alzheimer's.

The FDA has approved the first new Alzheimer's drug in nearly 20 years. Stephen Salloway digs into what it means for patients and for the disease's future.

The FDA approved Alzheimer's disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don't yet have.

Researchers have conducted an early human trial for a light- and sound-based treatment for Alzheimer's disease. The results are promising, they say.

Increases in "bad" bacteria and decreases in "good" bacteria in older adults' gums is associated with a biomarker for Alzheimer's disease, researchers find.

"...this pollution is everywhere and could explain the increased number of people impacted by Alzheimer's disease across the world."

A new study that links specific gut bacteria to neurodegenerative diseases could one day lead to treatments for Alzheimer's, Parkinson's, and ALS.

Experimental Alzheimer's drugs have shown little success in slowing the disease. New research in mice shows that unclogging the brain's "drain" may help.